Bladder cancer: current management and opportunities for a personalized approach.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  The Mount Sinai journal of medicine, New York

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/msj.20224PMID 21105122
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

  2010cited by this paper
• Phase II study of sunitinib in patients with metastatic urothelial cancer.

  2010cited by this paper
• Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC).

  2010cited by this paper
• Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics

  2010cited by this paper
• Dasatinib Is Preclinically Active against Src-Overexpressing Human Transitional Cell Carcinoma of the Urothelium with Activated Src Signaling

  2010cited by this paper
• A phase II trial of neoadjuvant erlotinib in patients with muscle‐invasive bladder cancer undergoing radical cystectomy: clinical and pathological results

  2010cited by this paper
• International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity

  2010cited by this paper
• A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma

  2009cited by this paper
• Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy.

  2009cited by this paper
• Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.

  2009cited by this paper
• Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer

  2009cited by this paper
• Inactivation of p53 and Pten promotes invasive bladder cancer.

  2009cited by this paper
• Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

  2009cited by this paper
• Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.

  2007cited by this paper
• Validation study of the prediction system for clinical response of M‐VAC neoadjuvant chemotherapy

  2007cited by this paper
• Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer

  2007cited by this paper
• Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma

  2007cited by this paper
• Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.

  2007cited by this paper
• Clinical model of lifetime cost of treating bladder cancer and associated complications.

  2006cited by this paper
• Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.

  2006cited by this paper
• A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

  2006cited by this paper
• Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

  2006cited by this paper
• Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.

  2006cited by this paper
• Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

  2006cited by this paper
• Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.

  2006cited by this paper
• Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

  2006cited by this paper
• Phase II trial of carboplatin and paclitaxel in cisplatin‐pretreated advanced transitional cell carcinoma

  2005cited by this paper
• Predicting Response to Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Neoadjuvant Chemotherapy for Bladder Cancers through Genome-Wide Gene Expression Profiling

  2005cited by this paper
• Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder

  2004cited by this paper
• p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.

  2004cited by this paper
• Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

  2004cited by this paper
• Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.

  2004cited by this paper
• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

  2003cited by this paper
• A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.

  2003cited by this paper
• Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.

  2002cited by this paper
• Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.

  2002cited by this paper
• Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

  2001cited by this paper
• Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer

  2001cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

  2000cited by this paper
• A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum

  1998cited by this paper
• A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer.

  1998cited by this paper
• p53 and treatment of bladder cancer

  1997cited by this paper
• Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

  1997cited by this paper
• Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma.

  1997cited by this paper
• Accumulation of nuclear p53 and tumor progression in bladder cancer.

  1994cited by this paper
• A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1992cited by this paper
• Carcinoma in situ.

  1992cited by this paper
• A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

  1990cited by this paper
• Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.

  1985cited by this paper
• The significance of lamina propria invasion on the prognosis of patients with bladder tumors.

  1980cited by this paper

• Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer

  2021cites this paper
• Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/β-catenin pathway and upregulating PTEN

  2021cites this paper
• Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with HER2 gene amplification: A case report.

  2020cites this paper
• The Influence of Race on Overall Survival in Patients with Newly Diagnosed Bladder Cancer

  2015cites this paper
• Via de sinalização mTOR no carcinoma urotelial da bexiga

  2014cites this paper
• Diallyl trisulfide-induced apoptosis of bladder cancer cells is caspase-dependent and regulated by PI3K/Akt and JNK pathways.

  2014cites this paper
• Biomarkers for bladder cancer management: present and future.

  2014cites this paper
• Featured Review Article Biomarkers for bladder cancer management: present and future

  2014cites this paper
• Inhibiting Invasion into Human Bladder Carcinoma 5637 Cells with Diallyl Trisulfide by Inhibiting Matrix Metalloproteinase Activities and Tightening Tight Junctions

  2013cites this paper
• Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index.

  2012cites this paper